What is EpiPaws?
EpiPaws operates at the intersection of biotechnology and consumer pet care, providing a specialized DNA-based age testing service for dogs and cats. By enabling pet owners, veterinarians, and animal shelters to determine the biological age of animals through simple at-home swabbing, the company fills a critical gap in veterinary diagnostics. This data-driven approach allows for more precise health management and proactive care, positioning EpiPaws as a leader in the emerging field of animal wellness technology. Their service model, which delivers comprehensive results within a 4-6 week window, is designed to scale across both direct-to-consumer and professional veterinary channels.
How much funding has EpiPaws raised?
EpiPaws has raised a total of $145K across 1 funding round:
Debt
$145K
Debt (2025): $145K, investors not publicly disclosed
Key Investors in EpiPaws
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for EpiPaws?
Following this late-stage financing, EpiPaws is expected to prioritize the expansion of its diagnostic infrastructure and the broadening of its market reach. The strategic allocation of these funds will likely focus on enhancing laboratory throughput to reduce turnaround times and investing in research to correlate age data with specific health outcomes. As the company matures, it is poised to integrate its findings into broader veterinary health platforms, potentially establishing a new standard for preventative care in the pet industry. The focus remains on leveraging scientific insights to drive long-term value for stakeholders and pet owners alike.
See full EpiPaws company page
